Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase
Cee, V.J., Cheng, A.C., Romero, K., Bellon, S., Mohr, C., Whittington, D.A., Bak, A., Bready, J., Caenepeel, S., Coxon, A., Deak, H.L., Fretland, J., Gu, Y., Hodous, B.L., Huang, X., Kim, J.L., Lin, J., Long, A.M., Nguyen, H., Olivieri, P.R., Patel, V.F., Wang, L., Zhou, Y., Hughes, P., Geuns-Meyer, S.(2009) Bioorg Med Chem Lett 19: 424-427
- PubMed: 19062275 
- DOI: https://doi.org/10.1016/j.bmcl.2008.11.056
- Primary Citation of Related Structures:  
3DA6, 3EFW, 3EWH - PubMed Abstract: 
Selective small molecule inhibitors of Tie-2 kinase are important tools for the validation of Tie-2 signaling in pathological angiogenesis. Reported herein is the optimization of a nonselective scaffold into a potent and highly selective inhibitor of Tie-2 kinase.
Organizational Affiliation: 
Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Bldg. 1000, Cambridge, MA 02139, USA. vcee@amgen.com